OBJECTIVE: To retrieve and analyze the available literature related to treatment for corona virus disease-19（ COVID-19）

so as to provide reference of evidence-based medicine for future treatment. METHODS:Pub Med

Clinical Trial. gov and Chinese Clinical Trial Registry were retrieved to collect available literature related to treatment for COVID-19. Literature were screened by two reviewers independently in accordance with the inclusion and exclusion criteria. Classification and analysis were performed according to the research drug categories. RESULTS: Two case reports suggested that radixivir

lopinavir/ritonavir and abidol may be effective in the treatment of COVID-19; one retrospective cohort study found that the efficacy of arbidol and lopinavir/ritonavir was unclear; in vitro studies suggested that chloroquine and darunavir had anti-virus activity against severe acute respiratory syndrome coronavirus 2（ SARS-CoV-2）; the evidence of ribavirin and interferon in the treatment of COVID-19 was based primarily on circumstantial evidence of the treatment of severe acute respiratory syndrome coronavirus（ SARS-Co V） and Middle East respiratory syndrome coronavirus（ MERS-Co V）. At present

multiple randomized controlled trials evaluating the efficacy and safety of the above drugs in the treatment of COVID-19 have been conducted. CONCLUSIONS: Although the current antiviral treatment of COVID-19 is not supported by high-quality evidence-based medicine

a number of studies have been launched to evaluate the clinical efficacy of traditional Chinese and western medicine treatment regimens

which will provide high-quality evidence for the treatment of COVID-19.